In initial studies with yeast cells it was found that the primary target of the antidepressant chlorimipramine (Anafranil, CIBA-Geigy) and the anti-leprosy drug clofazimine (Lamprene, CIBA-Geigy) was the mitochondrion (Hughes & Wilkie 1970 . Both drugs inhibited the respiratory chain, although by different mechanisms. The oxygen uptake of isolated rat liver mitochondria was affected in a similar way to that of the intact yeast mitochondria. When these studies were extended to human skin fibroblast cultures (Wilkie & Delhanty 1970 , Delhanty et al. 1974 , Mittwoch & Wilkie 1971 , both drugs again had a direct effect on oxygen uptake in the human cells similar to that in yeast cells. The significant finding in this series of experiments was that SV-40 transformed cells (cancer type) were much more susceptible to the inhibitory effects of the drugs than the non-transformed fibroblasts. Results with chlorimipramine on transformed cells are included in the above references, while clofazimine results showed that about 2 jsg/ml in the culture medium was a lethal dose for transformed fibroblasts but about 8 jig/ml was required to kill non-transformed cultures (unpublished results).
It was noted that the respiratory rate of transformed cells was significantly less than their normal counterparts in oxygen electrode studies (Wilkie & Delhanty 1970 In-vivo studies Experiments were begun with inducible tumours in mice, in an attempt to assess anticancer activity of these antimitochondrial agents in vivo. These experiments were also carried out in collaboration with Dr MacPherson and the results obtained with chlorimipramine are summarized in Table 2 . These show significant antitumour activity of the drug, not only on primary tumour development but also on the development of secondary tumours in the lungs. This latter effect was not unexpected, since chlorimipramine is known to accumulate and reach high concentration in the lungs and brain of experimental animals administered the drug (Herrman & Stierlin 1968 , Jaramills & Guth 1963 , Faigle & Dieterle 1973 . Dosages used in our experiments were low, mainly about 10 mg/kg and, in one case, approximately 40 mg/kg compared with the LD50 for subcutaneous administration in mice of 245 mg/kg (Jaramills & Guth 1963) . The treatment produced no detectable side effects. weeks in A and B after which the mice were sacrificed. In C, treatment was for 3 weeks and mice were sacrificed at 5 weeks. It was noted that the culture of carcinoma cells used in experiment 4 was less vigorous than in the other experiments and probably accounted for the low take and slow deveropment of primary tumours in the controls.
Antimitochondrial activity of cancer drugs
The idea that some of the anticancer drugs currently employed may manifest their clinical usefulness primarily through antimitochondrial activity is not new (Gosalvez et al. 1974 ), but critical experiments designed to show this have yet to be performed. Our finding that daunorubicin selectively blocks mitochondrial transcription in intact yeast cells and inhibits RNA synthesis in isolated rat liver mitochondria (Evans et al. 1973) provides some support for the hypothesis in the case of this antileukaemic agent. The related drug doxorubicin has very similar properties to daunorubicin but is marginally better able to discriminate against the mitochondria in the yeast cell. At high concentrations (50-100 i.g/ml), these drugs depress oxygen uptake in yeast cells in the oxygen electrode. There is evidence that the serious side effect of these drugs, namely cardiac arrest, is due to depression of mitochondrial biogenesis in heart muscle leading to structural aberration (Bertazzoli & Ghione 1977) , a fact which would seem to support the general hypothesis. Further support comes from our studies with the antineoplastic agents pyrimethamine and methotrexate. These folate analogues selectively blocked mitochondrial protein synthesis in yeast cells (Stone & Wilkie 1974 , Stone & Wilkie 1975 and appeared to have similar activity in human fibroblasts (Kirk et al. 1976) . The critical effect of the drugs seemed to be blockage of formylation of methionyl-tRNA which is necessary for initiation of protein synthesis in mitochondria, but not for cellular protein synthesis.
Other anticancer drugs which selectively blocked mitochondrial biogenesis in yeast cells in our tests were bleomycin, 5-fluorouracil, 2-6 diaminopurine, streptozocin and mitoguazone (methylglyoxal bisguanylhydrazone). These drugs together with doxorubicin, daunorubicin and the folate analogues also cause genetic lesions in the mitochondria of yeast cells, and block mitochondrial biogenesis. The suggestion is made that antineoplastic drugs have been produced, some, perhaps many, of which have primary antimitochondrial activity.
Inhibitors of mitochondrial function such as chlorimipramine and clofazimine, on the other hand, have no direct effect on mitochondrial biogenesis or mutagenesis and so may be less toxic for this reason. They also have the merit of relatively low toxicity compared to cytotoxic drugs and so could be administered for extensive periods. Furthermore, they have tissue specificity: lung and brain in the case of chlorimipramine, and reticuloendothelial system and subcutaneous layers for clofazimine (Connalty 1966) .
In the hypothesis developed here, a basic requirement in the efficiency of antimitochondrial drugs would be that neoplastic cells have mitochondrial deficiency as their weak spot. Since there are numerous reports in the literature of mitochondrial aberration of one kind or another in cancer cells (e.g. Sato et al. 1973 , Pedersen & Morris 1974 , Martin et al. 1974 , Melnick et al. 1977 , this requirement would appear to be met in some at least, if not most, cases.
